NEXT Oncology, an Avacare business

12/05/2025

Thank you to the American Association for Cancer Research (AACR) for this fascinating roundtable on dose optimization featuring our own Anthony Tolcher.

Experts discussed challenges and opportunities for dose optimization of cancer treatments at the 2025 AACR-Industry Roundtable.

11/27/2025

11/20/2025

Today on Day, we remember our friend and colleague Theresa Mays Hutchings.

11/12/2025

Congratulations to our colleagues at TOLREMO therapeutics!

“It is remarkable to see such rapid, deep and durable responses in NSCLC patients who had exhausted all prior treatments. TT125-802’s mechanism targeting non-oncogene addiction offers a novel approach to improving clinical outcomes for patients in this high-need setting.” Omar Saavedra Santa Gadea, NEXT Oncology, Barcelona

https://www.tolremo.com/press-releases/2025/20/8/tolremo-therapeutics-completes-first-in-human-dose-escalation-for-tt125-802-and-presents-solid-tumor-monotherapy-results-at-esmo-2025

11/05/2025

We are delighted to announce our expansion to Osaka, J*pan in collaboration with Dr. Toshio Shimizu and Kansai Medical University.

Read more:

With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. [SAN ANTONIO, TX – November 5, 2025] NEXT Oncology, an Avacare business, has expanded its services to Asia through a strategic partnership with Kansai Medical University in Osaka, J*p...

10/24/2025

We were proud to join our colleagues and collaborators at the SPARC Summit—an inspiring forum hosted by Bayer that brought together leaders in early-phase oncology research.

NEXT Oncology is honored to be working with Bayer across five different Phase I trials, advancing innovative cancer therapies through global collaboration. Events like this reflect the shared commitment to accelerating progress in oncology through partnership and scientific exchange.

A big thank you to the Bayer team and all who participated in this impactful event.

hashtag hashtag hashtag hashtag hashtag

09/11/2025

Congratulations to our colleagues at Revolution Medicines on these groundbreaking trials. We are proud to work with you.

https://www.clinicaltrialsarena.com/newsletters/revolution-medicines-daraxonrasib-phase-i-results-2/

09/03/2025

We are happy to welcome Faran S Polani, MD to the NEXT Oncology team in our Dallas office!

08/27/2025

Don't miss this learning opportunity at the 2025 Summit for Novel Therapeutics in Oncology & Precision Medicine in Cancer (STOP Cancer), featuring Anthony Tolcher and Shiraj Sen!

https://ce.horizoncme.com/content/2025-summit-novel-therapeutics-oncology-precision-medicine-cancer-stop-cancer -tabs-node-course-default2

08/14/2025

ICYMI:We’re proud to announce that results from a Phase 1 clinical trial led by Ildefonso Rodriguez-Rivera have been published in Nature Medicine. The study evaluated precemtabart tocentecan (precem-TcT) in collaboration with EMD Serono, Inc. in patients with metastatic colorectal cancer and showed encouraging early activity and manageable safety.

This publication reflects our continued commitment to advancing first-in-human cancer research and improving outcomes for patients with limited treatment options.

Read more here: http://bit.ly/46LssPl

Phase 1 trial findings published in Nature Medicine show promise for a new approach to targeting colorectal cancer and other tumors expressing CEACAM5. NEXT Oncology’s Dr. Ildefonso Ismael Rodriguez Rivera, a medical oncologist and hematologist in the San Antonio office, has led an innovative Phas...

08/07/2025

We’re proud to announce that results from a Phase 1 clinical trial led by Ildefonso Rodriguez-Rivera have been published in Nature Medicine. The study evaluated precemtabart tocentecan (precem-TcT) in collaboration with EMD Serono, Inc. in patients with metastatic colorectal cancer and showed encouraging early activity and manageable safety.

This publication reflects our continued commitment to advancing first-in-human cancer research and improving outcomes for patients with limited treatment options.

Read more here: http://bit.ly/46LssPl